An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Several lines of schizophrenia (SZ) research suggest that a functional downregulation of the prefrontal cortex GABAergic neuronal system is mediated by a promoter hypermethylation, presumably catalyzed by an increase in DNA-methyltransferase-1 (DNMT-1) expression. This promoter hypermethylation may be mediated not only by DNMT-1 but also by an entire family of de novo DNA-methyltransferases, such as DNA-methyltransferase-3a (DNMT-3a) and -3b (DNMT-3b). To verify the existence of an overexpression of DNMT-3a and DNMT-3b in the brain of schizophrenia patients (SZP), we compared their mRNA expression in Brodmann’s area 10 (BA10) and in the caudate nucleus and putamen obtained from the Harvard Brain Tissue Resource Center (Belmont, MA) from both nonpsychiatric subjects (NPS) and SZP. Our results demonstrate that DNMT-3a and DNMT-1 are expressed and co-localize in distinct GABAergic neuron populations whereas DNMT-3b mRNA is virtually undetectable. We also found that unlike DNMT-1, which is frequently overexpressed in telencephalic GABAergic neurons of SZP, DNMT-3a mRNA is overexpressed only in layers I and II GABAergic interneurons of BA10. To ascertain whether these DNMT expression differences observed in brain tissue could also be detected in peripheral tissues, we studied whether DNMT-1 and DNMT-3a mRNAs were overexpressed in peripheral blood lymphocytes (PBL) of SZP. Both DNMT-1 and DNMT-3a mRNAs are expressed in the PBL and although DNMT-3a mRNA levels in the PBL are approximately 1/10 of those of DNMT-1, the comparison of the PBL content in NPS and SZP showed a highly significant 2-fold increase of both DNMT-1 and DNMT-3a mRNA in SZP. These changes were unaffected by the dose, the duration, or the type of antipsychotic treatment. The upregulation of DNMT-1 and to a lesser extent that of DNMT-3a mRNA in and PBL of SZP supports the concept that this readily available peripheral cell type can express an epigenetic variation of specific biomarkers relevant to SZ morbidity. Hence, PBL studies may become useful to investigate a diagnostic epigenetic marker of SZ morbidity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297 · cited 2×
“…hypothesis supported by current schizophrenia (SZ) reports from laboratories throughout the world is that a downregulation of telencephalic GABAergic transmission is one of the key diagnostic signs of SZ morbidity (Benes et al., 2001, Guidotti et al., 2005, Lewis et al., 2005, Costa et al 2009).”
BackgroundGABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder
Benes, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00225-1 · Cited by 1,082 · cited 1×
“one of the key diagnostic signs of SZ morbidity (Benes and Berretta, 2001; Guidotti et al., 2005; Lewis et al., 2005; Costa et al 2009).”
BackgroundAkbarian, S. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160008002 · Cited by 1,002
Epigenomic Profiling Reveals DNA-Methylation Changes Associated with Major Psychosis
Mill, J., Tang, T., Kaminsky, Z., Khare, T., Yazdanpanah, S., Bouchard, L., Jia, P., Assadzadeh, A., Flanagan, J., Schumacher, A., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.01.008 · Cited by 773 · cited 1×
“, 2008), and other genes (Mill et al., 2008) are downregulated in distinct GABAergic neuronal populations located in specific cortical layers or proximal to pyramidal hippocampal neurons or in the basal ganglia of SZ patients (SZP) (Veldic et al.”
BackgroundEpigenetic mechanisms in memory formation
Levenson, J. M., & Sweatt, J. D. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1604 · Cited by 767
Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars
Benes, F. M., Lim, B., Matzilevich, D., Walsh, J. P., Subburaju, S., & Minns, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703806104 · Cited by 483 · cited 2×
“Interestingly, HDAC1 expression associated with a downregulation of GAD67 was found to be increased in the prefrontal cortex of SZP (Benes et al., 2007; Sharma et al., 2008).”
BackgroundPoulter, M. O., Du, L., Weaver, I. C. G., Palkovits, M., Faludi, G., Merali, Z., Szyf, M., & Anisman, H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.028 · Cited by 331 · cited 3×
“The increase of DNMT1 and DNMT3a mRNA in brains of SZP is probably specific to this illness because in the brain of suicidal/depressed patients, an increase of DNMT3b but not DNMT1 or DNMT3a mRNA has been implicated in the hypermethylation of the GABAA receptor α1 promoter region (Poulter et al., 2008).”
BackgroundGABAergic dysfunction in schizophrenia: new treatment strategies on the horizon
Guidotti, A., Auta, J., Davis, J. M., Dong, E., Grayson, D. R., Veldic, M., Zhang, X., & Costa, E. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2212-8 · Cited by 262 · cited 1×
“…hypothesis supported by current schizophrenia (SZ) reports from laboratories throughout the world is that a downregulation of telencephalic GABAergic transmission is one of the key diagnostic signs of SZ morbidity (Benes et al., 2001, Guidotti et al., 2005, Lewis et al., 2005, Costa et al 2009).”
BackgroundSelf-citation
Cited by
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Matrisciano, F., Tueting, P., Dalal, I., Kadriu, B., Grayson, D. R., Davis, J. M., Nicoletti, F., & Guidotti, A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.013 · Cited by 271
Self-citationThe Dynamics of DNA Methylation in Schizophrenia and Related Psychiatric Disorders
Grayson, D. R., & Guidotti, A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.125 · Cited by 267
Self-citationAn epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
MicroRNAs as biomarkers for CNS disease
Rao, P., Benito, E., & Fischer, A. (2013) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2013.00039 · Cited by 171
Metadata
- Authors
- Zhubi, A., Veldic, M., Puri, N. V., Kadriu, B., Caruncho, H., Loza, I., Sershen, H., Lajtha, A., Smith, R. C., Guidotti, A., Davis, J. M., & Costa, E.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 111
- Issue
- 1-3
- Pages
- 115-122
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2092981720
- Cited by
- 129
- References
- 8
- FWCI
- 5.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.